Summary

The global Parenteral Drugs market size is predicted to grow from US$ 17050 million in 2025 to US$ 21890 million in 2031; it is expected to grow at a CAGR of 4.3% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Parenteral Drug (LVP, SVP) is defined as one intended for injection through the skin or other external boundary tissue, rather than through the alimentary canal, so that active substances they contain are administered, using gravity or force, directly into a blood vessel, organ, tissue, or lesion. They are infused when administered intravenously (IV), or injected when administered intramuscularly (IM), or subcutaneously into the human body. A large volume parenteral (LVP) is a unit dose container of greater than 100ml that is terminally sterilized by heat. Small volume parenteral (SVP) is a "catch-all" for all non-LVP parenterals products except biologicals.
The global pharmaceutical market is approximately $1.47 trillion, with a CAGR of approximately 5% expected over the next six years. The pharmaceutical market includes chemical drugs and biological drugs.
The driving factors of the pharmaceutical market mainly include: increased demand for healthcare, advances in pharmaceutical technology and rising prevalence of chronic diseases, and increased pharmaceutical R&D activities and investments. However, the industry also faces various challenges such as strict market regulation, high R&D costs, expiration of drug patents, and declining revenues. Companies need to continue to innovate and adapt to these challenges to remain competitive in the market. In addition, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to respond flexibly to emerging public health needs.
As the global population aging trend intensifies, the proportion of the elderly population is increasing year by year. This group of people is more susceptible to chronic diseases, which often require long-term treatment and may be accompanied by insufficient nutritional intake. Parenteral drugs, especially parenteral nutrition drugs, provide important nutritional support and treatment for these patients.
Increased medical demand: The demand for medical services among the elderly population has increased significantly, especially the patient group that requires parenteral nutrition support and treatment, which has further promoted the development of the parenteral drug market.
Rising incidence of chronic diseases: With the change of lifestyle and the aggravation of environmental pollution, the incidence of chronic diseases has increased year by year. These chronic diseases, such as diabetes, cardiovascular disease, kidney disease, etc., usually require long-term treatment and may be accompanied by insufficient nutritional intake.
Demand for parenteral drug treatment: Parenteral drugs provide effective treatment for these chronic disease patients and meet their treatment needs, thereby promoting the development of the parenteral drug market.
LP Information, Inc. (LPI) ' newest research report, the “Parenteral Drugs Industry Forecast” looks at past sales and reviews total world Parenteral Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Parenteral Drugs sales for 2025 through 2031. With Parenteral Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Parenteral Drugs industry.
This Insight Report provides a comprehensive analysis of the global Parenteral Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Parenteral Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Parenteral Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Parenteral Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Parenteral Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Parenteral Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
LVP Drug
SVP Drug
Segmentation by Application:
Hospitals
Medical Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Ostuka Pharmaceutical
Teva Pharmaceutical Industries
Kelun Pharma
Cook Pharmica
Patheon
BAG Healthcare
Beximco Pharma
Baxter Healthcare Corporation
B. Braun
Fresenius
Albert David
BML Parenteral Drugs
Pfizer (Hospira)
SSY Group
Ozon Pharmaceuticals Ltd
Aspen Holdings
PSI Ltd
Cisen
AXA Parenterals Ltd
Acebright
Southwest Pharmaceutical
Abbott
Key Questions Addressed in this Report
What is the 10-year outlook for the global Parenteral Drugs market?
What factors are driving Parenteral Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Parenteral Drugs market opportunities vary by end market size?
How does Parenteral Drugs break out by Type, by Application?

ページTOPに戻る

List of Tables/Graphs

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Parenteral Drugs Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Parenteral Drugs by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Parenteral Drugs by Country/Region, 2020, 2024 & 2031
2.2 Parenteral Drugs Segment by Type
2.2.1 LVP Drug
2.2.2 SVP Drug
2.3 Parenteral Drugs Sales by Type
2.3.1 Global Parenteral Drugs Sales Market Share by Type (2020-2025)
2.3.2 Global Parenteral Drugs Revenue and Market Share by Type (2020-2025)
2.3.3 Global Parenteral Drugs Sale Price by Type (2020-2025)
2.4 Parenteral Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Medical Centers
2.4.3 Others
2.5 Parenteral Drugs Sales by Application
2.5.1 Global Parenteral Drugs Sale Market Share by Application (2020-2025)
2.5.2 Global Parenteral Drugs Revenue and Market Share by Application (2020-2025)
2.5.3 Global Parenteral Drugs Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Parenteral Drugs Breakdown Data by Company
3.1.1 Global Parenteral Drugs Annual Sales by Company (2020-2025)
3.1.2 Global Parenteral Drugs Sales Market Share by Company (2020-2025)
3.2 Global Parenteral Drugs Annual Revenue by Company (2020-2025)
3.2.1 Global Parenteral Drugs Revenue by Company (2020-2025)
3.2.2 Global Parenteral Drugs Revenue Market Share by Company (2020-2025)
3.3 Global Parenteral Drugs Sale Price by Company
3.4 Key Manufacturers Parenteral Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Parenteral Drugs Product Location Distribution
3.4.2 Players Parenteral Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Parenteral Drugs by Geographic Region
4.1 World Historic Parenteral Drugs Market Size by Geographic Region (2020-2025)
4.1.1 Global Parenteral Drugs Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Parenteral Drugs Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Parenteral Drugs Market Size by Country/Region (2020-2025)
4.2.1 Global Parenteral Drugs Annual Sales by Country/Region (2020-2025)
4.2.2 Global Parenteral Drugs Annual Revenue by Country/Region (2020-2025)
4.3 Americas Parenteral Drugs Sales Growth
4.4 APAC Parenteral Drugs Sales Growth
4.5 Europe Parenteral Drugs Sales Growth
4.6 Middle East & Africa Parenteral Drugs Sales Growth
5 Americas
5.1 Americas Parenteral Drugs Sales by Country
5.1.1 Americas Parenteral Drugs Sales by Country (2020-2025)
5.1.2 Americas Parenteral Drugs Revenue by Country (2020-2025)
5.2 Americas Parenteral Drugs Sales by Type (2020-2025)
5.3 Americas Parenteral Drugs Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Parenteral Drugs Sales by Region
6.1.1 APAC Parenteral Drugs Sales by Region (2020-2025)
6.1.2 APAC Parenteral Drugs Revenue by Region (2020-2025)
6.2 APAC Parenteral Drugs Sales by Type (2020-2025)
6.3 APAC Parenteral Drugs Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Parenteral Drugs by Country
7.1.1 Europe Parenteral Drugs Sales by Country (2020-2025)
7.1.2 Europe Parenteral Drugs Revenue by Country (2020-2025)
7.2 Europe Parenteral Drugs Sales by Type (2020-2025)
7.3 Europe Parenteral Drugs Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Parenteral Drugs by Country
8.1.1 Middle East & Africa Parenteral Drugs Sales by Country (2020-2025)
8.1.2 Middle East & Africa Parenteral Drugs Revenue by Country (2020-2025)
8.2 Middle East & Africa Parenteral Drugs Sales by Type (2020-2025)
8.3 Middle East & Africa Parenteral Drugs Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Parenteral Drugs
10.3 Manufacturing Process Analysis of Parenteral Drugs
10.4 Industry Chain Structure of Parenteral Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Parenteral Drugs Distributors
11.3 Parenteral Drugs Customer
12 World Forecast Review for Parenteral Drugs by Geographic Region
12.1 Global Parenteral Drugs Market Size Forecast by Region
12.1.1 Global Parenteral Drugs Forecast by Region (2026-2031)
12.1.2 Global Parenteral Drugs Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Parenteral Drugs Forecast by Type (2026-2031)
12.7 Global Parenteral Drugs Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Ostuka Pharmaceutical
13.1.1 Ostuka Pharmaceutical Company Information
13.1.2 Ostuka Pharmaceutical Parenteral Drugs Product Portfolios and Specifications
13.1.3 Ostuka Pharmaceutical Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Ostuka Pharmaceutical Main Business Overview
13.1.5 Ostuka Pharmaceutical Latest Developments
13.2 Teva Pharmaceutical Industries
13.2.1 Teva Pharmaceutical Industries Company Information
13.2.2 Teva Pharmaceutical Industries Parenteral Drugs Product Portfolios and Specifications
13.2.3 Teva Pharmaceutical Industries Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Teva Pharmaceutical Industries Main Business Overview
13.2.5 Teva Pharmaceutical Industries Latest Developments
13.3 Kelun Pharma
13.3.1 Kelun Pharma Company Information
13.3.2 Kelun Pharma Parenteral Drugs Product Portfolios and Specifications
13.3.3 Kelun Pharma Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Kelun Pharma Main Business Overview
13.3.5 Kelun Pharma Latest Developments
13.4 Cook Pharmica
13.4.1 Cook Pharmica Company Information
13.4.2 Cook Pharmica Parenteral Drugs Product Portfolios and Specifications
13.4.3 Cook Pharmica Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Cook Pharmica Main Business Overview
13.4.5 Cook Pharmica Latest Developments
13.5 Patheon
13.5.1 Patheon Company Information
13.5.2 Patheon Parenteral Drugs Product Portfolios and Specifications
13.5.3 Patheon Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Patheon Main Business Overview
13.5.5 Patheon Latest Developments
13.6 BAG Healthcare
13.6.1 BAG Healthcare Company Information
13.6.2 BAG Healthcare Parenteral Drugs Product Portfolios and Specifications
13.6.3 BAG Healthcare Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 BAG Healthcare Main Business Overview
13.6.5 BAG Healthcare Latest Developments
13.7 Beximco Pharma
13.7.1 Beximco Pharma Company Information
13.7.2 Beximco Pharma Parenteral Drugs Product Portfolios and Specifications
13.7.3 Beximco Pharma Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Beximco Pharma Main Business Overview
13.7.5 Beximco Pharma Latest Developments
13.8 Baxter Healthcare Corporation
13.8.1 Baxter Healthcare Corporation Company Information
13.8.2 Baxter Healthcare Corporation Parenteral Drugs Product Portfolios and Specifications
13.8.3 Baxter Healthcare Corporation Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Baxter Healthcare Corporation Main Business Overview
13.8.5 Baxter Healthcare Corporation Latest Developments
13.9 B. Braun
13.9.1 B. Braun Company Information
13.9.2 B. Braun Parenteral Drugs Product Portfolios and Specifications
13.9.3 B. Braun Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 B. Braun Main Business Overview
13.9.5 B. Braun Latest Developments
13.10 Fresenius
13.10.1 Fresenius Company Information
13.10.2 Fresenius Parenteral Drugs Product Portfolios and Specifications
13.10.3 Fresenius Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Fresenius Main Business Overview
13.10.5 Fresenius Latest Developments
13.11 Albert David
13.11.1 Albert David Company Information
13.11.2 Albert David Parenteral Drugs Product Portfolios and Specifications
13.11.3 Albert David Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Albert David Main Business Overview
13.11.5 Albert David Latest Developments
13.12 BML Parenteral Drugs
13.12.1 BML Parenteral Drugs Company Information
13.12.2 BML Parenteral Drugs Parenteral Drugs Product Portfolios and Specifications
13.12.3 BML Parenteral Drugs Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 BML Parenteral Drugs Main Business Overview
13.12.5 BML Parenteral Drugs Latest Developments
13.13 Pfizer (Hospira)
13.13.1 Pfizer (Hospira) Company Information
13.13.2 Pfizer (Hospira) Parenteral Drugs Product Portfolios and Specifications
13.13.3 Pfizer (Hospira) Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Pfizer (Hospira) Main Business Overview
13.13.5 Pfizer (Hospira) Latest Developments
13.14 SSY Group
13.14.1 SSY Group Company Information
13.14.2 SSY Group Parenteral Drugs Product Portfolios and Specifications
13.14.3 SSY Group Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 SSY Group Main Business Overview
13.14.5 SSY Group Latest Developments
13.15 Ozon Pharmaceuticals Ltd
13.15.1 Ozon Pharmaceuticals Ltd Company Information
13.15.2 Ozon Pharmaceuticals Ltd Parenteral Drugs Product Portfolios and Specifications
13.15.3 Ozon Pharmaceuticals Ltd Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Ozon Pharmaceuticals Ltd Main Business Overview
13.15.5 Ozon Pharmaceuticals Ltd Latest Developments
13.16 Aspen Holdings
13.16.1 Aspen Holdings Company Information
13.16.2 Aspen Holdings Parenteral Drugs Product Portfolios and Specifications
13.16.3 Aspen Holdings Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Aspen Holdings Main Business Overview
13.16.5 Aspen Holdings Latest Developments
13.17 PSI Ltd
13.17.1 PSI Ltd Company Information
13.17.2 PSI Ltd Parenteral Drugs Product Portfolios and Specifications
13.17.3 PSI Ltd Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 PSI Ltd Main Business Overview
13.17.5 PSI Ltd Latest Developments
13.18 Cisen
13.18.1 Cisen Company Information
13.18.2 Cisen Parenteral Drugs Product Portfolios and Specifications
13.18.3 Cisen Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 Cisen Main Business Overview
13.18.5 Cisen Latest Developments
13.19 AXA Parenterals Ltd
13.19.1 AXA Parenterals Ltd Company Information
13.19.2 AXA Parenterals Ltd Parenteral Drugs Product Portfolios and Specifications
13.19.3 AXA Parenterals Ltd Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 AXA Parenterals Ltd Main Business Overview
13.19.5 AXA Parenterals Ltd Latest Developments
13.20 Acebright
13.20.1 Acebright Company Information
13.20.2 Acebright Parenteral Drugs Product Portfolios and Specifications
13.20.3 Acebright Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 Acebright Main Business Overview
13.20.5 Acebright Latest Developments
13.21 Southwest Pharmaceutical
13.21.1 Southwest Pharmaceutical Company Information
13.21.2 Southwest Pharmaceutical Parenteral Drugs Product Portfolios and Specifications
13.21.3 Southwest Pharmaceutical Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Southwest Pharmaceutical Main Business Overview
13.21.5 Southwest Pharmaceutical Latest Developments
13.22 Abbott
13.22.1 Abbott Company Information
13.22.2 Abbott Parenteral Drugs Product Portfolios and Specifications
13.22.3 Abbott Parenteral Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
13.22.4 Abbott Main Business Overview
13.22.5 Abbott Latest Developments
14 Research Findings and Conclusion